Tohoku University

Kake Educational Institution

Keio University

Sbi Pharmaceuticals Co., Ltd.

Jichi Medical University

Kake Education Institution

Kanagawa Prefectural Hospital Organization Kanagawa Children's Medical Center

Kanagawa Prefectural Hospital Organisation Kanagawa Children's Medical Center

Takaaki Abe

Kenichiro Hayashi

Hitoshi Osaka

Teiji Tominaga

Tohru Tanaka

Yuji Matsumoto

Keiichi Murakami

Motowo Nakajima

Kiwamu Takahashi

Tomoyoshi Soga

Nobuo Yaegashi

Akihiko Miyauchi

Masahito Tachibana

Takanori Yamagata

Yukio Katori

Michiaki Unno

Eriko Jimbo

Fumika Nanto

Masakuni Horiguchi

Shinobu Ohnuma

Maiko Nagayasu

Susumu Ogawa

Yohei Honkura

Yoshihisa Tomioka

An object of the present invention is to provide a low molecular weight compound having a prophylactic or therapeutic action on cancer. A compound of the following formula (1), a compound of the following formula (2), or the like can be administered by a method such as oral administration to prevent or treat cancers such as colorectal cancer.

Prophylactic or therapeutic agent for cancer

An object of the present invention is to provide an agent for enhancing fertilization function of a mammal sperm, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient, and a method for enhancing fertilization function of a mammal sperm and a method for preparing a mammal fertilized egg, which use a low molecular compound which can be produced relatively easily and inexpensively. An agent comprising one or more compounds selected from the group consisting of compounds of the following formula (I), formula (II), and formula (III), and physiologically acceptable salts thereof when Ris OH is used as an agent for enhancing fertilization function of a mammal sperm.

Enhancer of fertilization function of sperm

A means for substantially improving mitochondrial dysfunction is provided. An aspect of the present invention relates to an agent for improving mitochondrial dysfunction, having a compound represented by the following formula, a stereoisomer or a salt thereof, or a solvate thereof, as an active ingredient. Another aspect of the present invention relates to a medicament or a pharmaceutical composition having the aforementioned compound, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active ingredient, for use in preventing or treating a disease or symptom caused by mitochondrial dysfunction. 

Agent for improving mitochondrial dysfunction, preventative or therapeutic agent for diseases or symptoms caused by mitochondrial dysfunction, and applications therefor

It is to provide an agent for preventing or improving hearing loss, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient. One or more compounds selected from the group consisting of compounds represented by the following formulas (I), (II), and (III) and a pharmaceutically acceptable salt of the compounds when Ris OH are used as an agent for preventing or improving hearing loss. 

Agent for preventing or ameliorating hearing impairment

It is an object of the present invention to provide a novel therapeutic agent and method for treating amyotrophic diseases, and more specifically a therapeutic agent and method for treating neurogenic amyotrophic disorders such as amyotrophic lateral sclerosis (ALS) and myogenic amyotrophic disorders such as sarcopenia or disuse muscle atrophy. Provided is a therapeutic agent for amyotrophic diseases that comprises one or more compounds selected from the group consisting of compounds represented by the formula (I), the formula (II) and the formula (III), and pharmaceutically acceptable salts of the compounds when Rrepresents OH. 

Therapeutic agent for amyotrophic disorders

An object of the present invention is to provide a biomarker capable of determining the onset risk or the stage of diabetic nephropathy (early-stage diabetic nephropathy in particular). Diabetic nephropathy is determined by measuring or quantitatively determining a concentration of phenyl sulfate or a salt thereof (a phenyl sulfate) contained in a biological sample, preferably plasma or urine, collected from a test subject to detect a phenyl sulfate. The present invention exhibits excellent effects particularly for stage determination for stage 1 (pre-nephropathy stage) to stage 3 (overt nephropathy stage), or for determination of onset risk of diabetic nephropathy (diabetic nephropathy at pre-nephropathy stage).

Marker for determining diabetic nephropathy

The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when Ris OH. 

Erythropoietin expression promoter

A therapeutic and/or prophylactic agent for renal anemia comprising ALAs and an erythropoietin production promoter comprising ALAs.

Erythropoietin production-promoting agent

The present invention relates to a method for diagnosing, and treating renal disease in a patient by having a test performed for detecting or quantifying one or more renal disease markers present in a test blood sample from the patient; and administering treatment to improve renal function. In particular embodiments, the test performed quantifies cis-aconitate, and the patient is identified as having the renal disease when a concentration of cis-aconitate present in the patient's test blood sample is higher than that of a control. Methods of the present invention can allow diagnosis and treatment of patients with early stage renal disease, such as early stage renal failure. Another aspect of the present invention relates to methods for screening for a prophylactic/therapeutic agent for treating renal disease using one or more renal disease markers.

Human renal disease marker substance

Growing community of inventors

Miyagi, Japan

Takaaki Abe